Efficacy of a Protracted Temozolomide Schedule in Patients With Progression After Standard Dose Temozolomide for High-Grade Gliomas
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Progression-free survival at 6-months
Until progression
No
Ufuk ABACIOGLU, MD
Study Chair
Marmara University Hospital, Radiation Oncology Department
Turkey: Ministry of Health
MU-RO-2005-1
NCT00575887
August 2006
February 2009
Name | Location |
---|